JNJ|Johnson & Johnson|가격:229.320|Chg%:-0.68

자세한 내용은 Johnson & Johnson 회사

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Johnson & Johnson 정보



종목 코드 JNJ

회사 이름Johnson & Johnson

상장일Oct 31, 2080

CEODuato (Joaquin Boix)

직원 수138100

유형Ordinary Share

회계 연도 종료Oct 31

주소One Johnson & Johnson Plaza

도시NEW BRUNSWICK

증권 거래소NASDAQ OMX NASDAQ Basic NYSE

국가United States of America

우편 번호08933

전화17325242455

웹사이트https://www.jnj.com/

종목 코드 JNJ

상장일Oct 31, 2080

CEODuato (Joaquin Boix)

Johnson & Johnson의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

356.30K

+22.28%

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

194.45K

+8.45%

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

114.63K

+17.45%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

85.01K

+0.07%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

24.91K

+57.22%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

23.57K

+45.46%

Ms. Vanessa Broadhurst

Executive Vice President - Global Corporate Affairs

23.00K

-2.57%

Ms. Kristen Mulholland

Chief Human Resources Officer, Executive Vice President

19.83K

+28.80%

Mr. Hubert Joly

Independent Director

5.00K

--

Ms. Marillyn A. Hewson

Lead Independent Director

3.00K

--

이름

이름/직위

직위

주식 보유

변동

Mr. Joaquin Boix Duato

Chairman of the Board, Chief Executive Officer

356.30K

+22.28%

Ms. Jennifer L. Taubert

Executive Vice President, Worldwide Chairman, Innovative Medicine

194.45K

+8.45%

Ms. Kathryn E. Wengel

Executive Vice President, Chief Technology Officer and Risk Officer

114.63K

+17.45%

Mr. Joseph J. Wolk

Chief Financial Officer, Executive Vice President

85.01K

+0.07%

Prof. Dr. John C. Reed, M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

24.91K

+57.22%

Ms. Elizabeth (Liz) Forminard

Executive Vice President, Chief Legal Officer

23.57K

+45.46%

수익 분석

통화: USD마지막 업데이트: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Oncology-DARZALEX

14.35B

15.24%

Immunology-STELARA

6.08B

6.45%

Cardiovascular-ELECTROPHYSIOLOGY

5.63B

5.98%

Surgery-General

5.56B

5.90%

Immunology-TREMFYA

5.16B

5.47%

기타

57.41B

60.95%

지역별USD

이름

수익

비율

United States

53.75B

57.07%

International

40.44B

42.93%

Europe

21.54B

22.86%

Asia-Pacific, Africa

14.03B

14.90%

Western Hemisphere, excluding U.S.

4.88B

5.18%

사업별

지역별

사업별USD

이름

수익

비율

Oncology-DARZALEX

14.35B

15.24%

Immunology-STELARA

6.08B

6.45%

Cardiovascular-ELECTROPHYSIOLOGY

5.63B

5.98%

Surgery-General

5.56B

5.90%

Immunology-TREMFYA

5.16B

5.47%

기타

57.41B

60.95%

주식 보유 통계

마지막 업데이트: Sun, May 10

주주

주주 유형

주주

비율

Vanguard Capital Management, LLC

6.51%

State Street Investment Management (US)

5.56%

BlackRock Institutional Trust Company, N.A.

5.44%

Vanguard Portfolio Management, LLC

2.64%

Geode Capital Management, L.L.C.

2.41%

기타

77.45%

주주

비율

Vanguard Capital Management, LLC

6.51%

State Street Investment Management (US)

5.56%

BlackRock Institutional Trust Company, N.A.

5.44%

Vanguard Portfolio Management, LLC

2.64%

Geode Capital Management, L.L.C.

2.41%

기타

77.45%

주주 유형

주주

비율

Investment Advisor

40.66%

Investment Advisor/Hedge Fund

23.83%

Research Firm

3.28%

Pension Fund

2.20%

Bank and Trust

2.14%

Insurance Company

1.62%

Sovereign Wealth Fund

1.48%

Hedge Fund

0.61%

Family Office

0.08%

기타

24.12%

기관 주식 보유



마지막 업데이트: Sun, Apr 5

보고 기간

기관 수

보유 주식

비율

변동

2026Q1

6338

1.78B

73.80%

-65.47M

2025Q4

6038

1.81B

75.24%

+5.09M

2025Q3

5885

1.79B

74.44%

+16.50K

2025Q2

5920

1.78B

73.89%

-7.65M

2025Q1

6002

1.80B

74.62%

+4.60M

2024Q4

5953

1.78B

74.14%

+8.28M

2024Q3

5699

1.77B

73.47%

+2.69M

2024Q2

5691

1.75B

72.75%

+9.12M

2024Q1

5685

1.73B

71.58%

-6.08M

2023Q4

5686

1.72B

71.40%

-7.80M

주주 활동



이름

보유 주식

비율

변동

Chg %

날짜

State Street Investment Management (US)

133.87M

5.56%

+1.66M

+1.26%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

130.93M

5.44%

+1.51M

+1.17%

Dec 31, 2025

Geode Capital Management, L.L.C.

57.95M

2.41%

+1.74M

+3.09%

Dec 31, 2025

JP Morgan Asset Management

39.68M

1.65%

+3.08M

+8.41%

Dec 31, 2025

State Farm Insurance Companies

34.11M

1.42%

--

Dec 31, 2025

Norges Bank Investment Management (NBIM)

33.46M

1.39%

+1.53M

+4.79%

Dec 31, 2025

Morgan Stanley Smith Barney LLC

23.96M

0.99%

-1.30M

-5.14%

Dec 31, 2025

Wellington Management Company, LLP

23.24M

0.96%

-2.59M

-10.04%

Dec 31, 2025

주식 배당금



지난 5년 동안 총 46.31B USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

Apr 14, 2026

JNJ.NB Interim Cash Dividend of gross USD 1.34 paid on Jun 09, 2026 going ex on May 26, 2026

May 26, 2026

Jun 09, 2026

May 26, 2026

Jan 02, 2026

JNJ.NB Final Cash Dividend of gross USD 1.3 paid on Mar 10, 2026 going ex on Feb 24, 2026

Feb 24, 2026

Mar 10, 2026

Feb 24, 2026

Jan 02, 2025

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025

Feb 18, 2025

Mar 04, 2025

Feb 18, 2025

Oct 15, 2024

JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024

Nov 26, 2024

Dec 10, 2024

Nov 26, 2024

Jul 17, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024

Aug 27, 2024

Sep 10, 2024

Aug 27, 2024

Apr 16, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024

May 21, 2024

Jun 04, 2024

May 20, 2024

Jan 02, 2024

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024

Feb 20, 2024

Mar 05, 2024

Feb 16, 2024

Oct 19, 2023

JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023

Nov 21, 2023

Dec 05, 2023

Nov 20, 2023

Jul 20, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023

Aug 28, 2023

Sep 07, 2023

Aug 25, 2023

Apr 18, 2023

JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023

May 23, 2023

Jun 06, 2023

May 22, 2023

주식 분할



날짜

배당락일

유형

비율

데이터 없음

날짜

배당락일

유형

비율

데이터 없음

Johnson & Johnson

자세한 내용은 Johnson & Johnson 회사

Johnson & Johnson 정보

Johnson & Johnson의 회사 임원진

수익 분석

주식 보유 통계

기관 주식 보유

주주 활동

관련 ETF

주식 배당금

주식 분할